Surovatamig as Consolidation Therapy in Participants with Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma with Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Trial Identifier: D7409C00001
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: May 2026
Primary Completion Date: August 2031
Study Completion Date: April 2032

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Adelaide, AU, 5000
AU Fitzroy, AU, 3065
AU Heidelberg, AU, 3084
AU Nedlands, AU, 6009
AU Perth, AU, 6847
AU Rockingham, AU, 6168
CA, AB Calgary, AB, CA, T2N 5G2
CA, BC Vancouver, BC, CA, V5Z 4E6
CA, NS Halifax, NS, CA, B3H 2Y9
CA, Ontario Hamilton, Ontario, CA, L8V 5C2
CA, Ontario Toronto, Ontario, CA, M5G 2L7
CA, QC Montréal, QC, CA, H2L 4M1
CA, QC Québec, QC, CA, G1J 1Z4
CA, Quebec Montréal, Quebec, CA, H3T 1E2
GB Edinburgh, GB, EH4 2XU
GB Hampshire, GB, SO16 6YD
GB Leeds, GB, LS9 7TF
GB London, GB, SE5 9RS
GB London, GB, NW1 2BU
GB Manchester, GB, M20 4BX
GB NOTTINGHAM, GB, NG5 1PB
GB Oxford, GB, OX3 7LE
GB Sutton, GB, SM2 5PT
TR Adapazarı, TR, 54100
TR Antalya, TR, 07025
TR Istanbul, TR, 34517
TR İstanbul, TR, 34899
TR İstanbul, TR, 34098
TR Kocaeli, TR, 41380
TR Mezitli, TR, 33200